Pharmacological Treatment of Alcohol use Disorder in Patients with Psychotic Disorders: A Systematic Review


Cite item

Full Text

Abstract

Background:Patients with psychotic disorders (PD) often have comorbid alcohol use disorder (AUD), which is typically treated pharmacologically. Up till now, no systematic review has examined the effectiveness and safety of AUD treatment in PD patients.

Objectives:This study aimed to systematically review the literature on (1) the effects of pharmacological treatments for AUD on drinking outcomes, (2) the side effects of the drugs, and (3) the effects of polypharmacy in patients with comorbid AUD and PD.

Methods:Bibliographic searches were conducted in MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and PsycINFO. At least two reviewers extracted the data, assessed the risk of bias, and performed the qualitative synthesis of the collected evidence.

Results:Twelve eligible studies were identified, half being randomized controlled trials (RCTs). Three studies examined disulfiram, nine naltrexone, two acamprosate, and one nalmefene by comparing the effects of treatment to placebo, baseline, or pharmacological agents. Disulfiram and naltrexone were shown to reduce alcohol intake. Regarding acamprosate, the findings were mixed. Nalmefene decreased alcohol intake. All pharmacological agents appeared safe to use as AUD monotherapy, but cardiac events were reported when combining naltrexone and disulfiram. Nine studies had a high risk of bias, and three had some other concerns.

Conclusion:The studies provide tentative support for the use of naltrexone and disulfiram in this population, although combinations of pharmacological AUD treatments and other polypharmacy remain unexplored. The studies had high adherence rates that are hardly replicable in real-world settings. Thus, the findings should be confirmed in larger high quality efficacy and effectiveness RCTs with longer follow-ups.

About the authors

Niels Rosenstand

Unit for Psychiatric Research, Department of Clinical Research, University of Southern Denmark

Email: info@benthamscience.net

Anette Nielsen

Unit for Psychiatric Research, Department of Clinical Research, University of Southern Denmark

Email: info@benthamscience.net

Lotte Skøt

Unit for Psychiatric Research, Department of Clinical Research, University of Southern Denmark

Email: info@benthamscience.net

Simon Anhøj

Unit for Psychiatric Research, Department of Clinical Research, University of Southern Denmark

Email: info@benthamscience.net

Dorthe Nielsen

Unit for Psychiatric Research, Department of Clinical Research, University of Southern Denmark

Email: info@benthamscience.net

Mikkel Højlund

, Drug Treatment Center Odense

Email: info@benthamscience.net

Angelina Mellentin

Unit for Psychiatric Research, Department of Clinical Research, University of Southern Denmark

Author for correspondence.
Email: info@benthamscience.net

References

  1. Mueser, K.T.; Yarnold, P.R.; Levinson, D.F.; Singh, H.; Bellack, A.S.; Kee, K.; Morisson, R.L.; Yadalam, K.G. Prevalence of substance abuse in schizophrenia: Demographic and clinical correlates. Schizophr. Bull., 1990, 16(1), 31-56. doi: 10.1093/schbul/16.1.31 PMID: 2333480
  2. Archibald, L.; Brunette, M.F.; Wallin, D.J.; Green, A.I. Alcohol use disorder and schizophrenia and schizoaffective disorders. Alcohol Res., 2019, 40(1) doi: 10.1186/2045-8118-11-26 PMID: 25678956
  3. Regier, D.A.; Farmer, M.E.; Rae, D.S.; Locke, B.Z.; Keith, S.J.; Judd, L.L.; Goodwin, F.K. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA, 1990, 264(19), 2511-2518. doi: 10.1001/jama.1990.03450190043026 PMID: 2232018
  4. Koskinen, J.; Löhönen, J.; Koponen, H.; Isohanni, M.; Miettunen, J. Prevalence of alcohol use disorders in schizophrenia - a systematic review and meta-analysis. Acta Psychiatr. Scand., 2009, 120(2), 85-96. doi: 10.1111/j.1600-0447.2009.01385.x PMID: 19374633
  5. Gerding, L.B.; Labbate, L.A.; Measom, M.O.; Santos, A.B.; Arana, G.W. Alcohol dependence and hospitalization in schizophrenia. Schizophr. Res., 1999, 38(1), 71-75. doi: 10.1016/S0920-9964(98)00177-7 PMID: 10427612
  6. Lorine, K.; Goenjian, H.; Kim, S.; Steinberg, A.M.; Schmidt, K.; Goenjian, A.K. Risk factors associated with psychiatric readmission. J. Nerv. Ment. Dis., 2015, 203(6), 425-430. doi: 10.1097/NMD.0000000000000305 PMID: 25974053
  7. Dixon, L. Dual diagnosis of substance abuse in schizophrenia: Prevalence and impact on outcomes. Schizophr. Res., 1999, 35(Suppl.), S93-S100. doi: 10.1016/S0920-9964(98)00161-3 PMID: 10190230
  8. Owen, R.R.; Fischer, E.P.; Booth, B.M.; Cuffel, B.J. Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatr. Serv., 1996, 47(8), 853-858. doi: 10.1176/ps.47.8.853 PMID: 8837158
  9. Sundhedsstyrelsen. NKR: Behandling af alkoholafhængighed. 2018. Available on: https://www.sst.dk/da/udgivelser/2018/nkr-behandling-af-alkoholafhaengighed
  10. National Institute for Health and Care Excellence. Alcohol-use disorders: Diagnosis, assessment and management of harmful drinking (high-risk drinking) and alcohol dependence; , 2011. Available on: https://www.nice.org.uk/guidance/cg115
  11. Food and Drug Administration. Drugs@FDA: FDA-approved drugs; , 2022. Available on: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
  12. European Medicines Agency. Medicines. 2022. Available on: https://www.ema.europa.eu/en/human-regulatory/post-authorisation/data-medicines-iso-idmp-standards/public-data-article-57-database
  13. European Medicines Agency. Development of medicinal products for the treatment of alcohol dependence; , 2010. Available on: https://www.ema.europa.eu/en/development-medicinal-products-treatment-alcohol-dependence
  14. National Collaborating Centre for Mental Health (UK). Alcohol-Use Disorders: Diagnosis, Assessment and Management of Harmful Drinking and Alcohol Dependence; British Psychological Society: Leicester, UK, 2011.
  15. Skinner, M.D.; Lahmek, P.; Pham, H.; Aubin, H.J. Disulfiram efficacy in the treatment of alcohol dependence: A meta-analysis. PLoS One, 2014, 9(2), e87366. doi: 10.1371/journal.pone.0087366 PMID: 24520330
  16. Donoghue, K.; Elzerbi, C.; Saunders, R.; Whittington, C.; Pilling, S.; Drummond, C. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: A meta-analysis. Addiction, 2015, 110(6), 920-930. doi: 10.1111/add.12875 PMID: 25664494
  17. Mann, K.; Torup, L.; Sørensen, P.; Gual, A.; Swift, R.; Walker, B.; van den Brink, W. Nalmefene for the management of alcohol dependence: Review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy. Eur. Neuropsychopharmacol., 2016, 26(12), 1941-1949. doi: 10.1016/j.euroneuro.2016.10.008 PMID: 27842940
  18. Fuller, R.K.; Branchey, L.; Brightwell, D.R.; Derman, R.M.; Emrick, C.D.; Iber, F.L.; James, K.E.; Lacoursiere, R.B.; Lee, K.K.; Lowenstam, I. Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA, 1986, 256(11), 1449-1455. doi: 10.1001/jama.1986.03380110055026 PMID: 3528541
  19. Mueser, K.T.; Noordsy, D.L.; Fox, L.; Wolfe, R. Disulfiram treatment for alcoholism in severe mental illness. Am. J. Addict., 2003, 12(3), 242-252. doi: 10.1111/j.1521-0391.2003.tb00652.x PMID: 12851020
  20. Nasrallah, H.A. Vulnerability to disulfiram psychosis. West. J. Med., 1979, 130(6), 575-577. PMID: 516699
  21. Kalk, N.J.; Lingford-Hughes, A.R. The clinical pharmacology of acamprosate. Br. J. Clin. Pharmacol., 2014, 77(2), 315-323. doi: 10.1111/bcp.12070 PMID: 23278595
  22. King, A.C.; Volpicelli, J.R.; Frazer, A.; O’Brien, C.P. Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology (Berl.), 1997, 129(1), 15-22. doi: 10.1007/s002130050156 PMID: 9122358
  23. Bart, G.; Schluger, J.H.; Borg, L.; Ho, A.; Bidlack, J.M.; Kreek, M.J. Nalmefene induced elevation in serum prolactin in normal human volunteers: Partial kappa opioid agonist activity? Neuropsychopharmacology, 2005, 30(12), 2254-2262. doi: 10.1038/sj.npp.1300811 PMID: 15988468
  24. Barnas, C.; Hummer, M.; Fleischhacker, W.W. Compliance problems in treatment of schizophrenic patients. Wien. Med. Wochenschr., 1998, 148(11-12), 281-283. PMID: 9746971
  25. National Institute for Health and Care Excellence. Coexisting severe mental illness and substance misuse: Community health and health and social care services; , 2016. Available on: https://www.nice.org.uk/guidance/ng58
  26. National Institute for Health and Care Excellence. Coexisting severe mental illness (psychosis) and substance misuse: Assessment and management in healthcare settings; , 2011. Available on: https://www.nice.org.uk/guidance/cg120
  27. Sundhedsstyrelsen. NKR: Udredning og behandling af personer med samtidig alkoholafhængighed og psykisk lidelse., 2019. Available on: https://www.sst.dk/da/udgivelser/2016/nkr-for-udredning-og-behandling-af-samtidig-alkoholafhaengighed-og-psykisk-lidelse
  28. Bellack, A.S.; Gearon, J.S. Substance abuse treatment for people with schizophrenia. Addict. Behav., 1998, 23(6), 749-766. doi: 10.1016/S0306-4603(98)00066-5 PMID: 9801714
  29. Bortolato, B.; Miskowiak, K.W.; Köhler, C.A.; Vieta, E.; Carvalho, A.F. Cognitive dysfunction in bipolar disorder and schizophrenia: A systematic review of meta-analyses. Neuropsychiatr. Dis. Treat., 2015, 11, 3111-3125. PMID: 26719696
  30. Sheffield, J.M.; Barch, D.M. Cognition and resting-state functional connectivity in schizophrenia. Neurosci. Biobehav. Rev., 2016, 61, 108-120. doi: 10.1016/j.neubiorev.2015.12.007 PMID: 26698018
  31. Marder, S.R.; Cannon, T.D. Schizophrenia. N. Engl. J. Med., 2019, 381(18), 1753-1761. doi: 10.1056/NEJMra1808803 PMID: 31665579
  32. Huhn, M.; Tardy, M.; Spineli, L.M.; Kissling, W.; Förstl, H.; Pitschel-Walz, G.; Leucht, C.; Samara, M.; Dold, M.; Davis, J.M.; Leucht, S. Efficacy of pharmacotherapy and psychotherapy for adult psychiatric disorders: A systematic overview of meta-analyses. JAMA Psychiatry, 2014, 71(6), 706-715. doi: 10.1001/jamapsychiatry.2014.112 PMID: 24789675
  33. Petrakis, I.L.; Leslie, D.; Rosenheck, R. Use of naltrexone in the treatment of alcoholism nationally in the Department of Veterans Affairs. Alcohol. Clin. Exp. Res., 2003, 27(11), 1780-1784. doi: 10.1097/01.ALC.0000095861.43232.19 PMID: 14634494
  34. Iheanacho, T.; Issa, M.; Marienfeld, C.; Rosenheck, R. Use of naltrexone for alcohol use disorders in the Veterans’ Health Administration: A national study. Drug Alcohol Depend., 2013, 132(1-2), 122-126. doi: 10.1016/j.drugalcdep.2013.01.016 PMID: 23434041
  35. Barnes, T.R.E.; Paton, C. Antipsychotic polypharmacy in schizophrenia: Benefits and risks. CNS Drugs, 2011, 25(5), 383-399. doi: 10.2165/11587810-000000000-00000 PMID: 21476610
  36. Baandrup, L. Polypharmacy in schizophrenia. Basic Clin. Pharmacol. Toxicol., 2020, 126(3), 183-192. doi: 10.1111/bcpt.13384 PMID: 31908124
  37. Lin, S.K. Antipsychotic Polypharmacy: A Dirty Little Secret or a Fashion? Int. J. Neuropsychopharmacol., 2020, 23(2), 125-131. doi: 10.1093/ijnp/pyz068 PMID: 31867671
  38. Higgins, J.P.T.; Thomas, J.; Chandler, J.; Cumpston, M.; Li, T.; Page, M.J.; Welch, V.A. Cochrane handbook for systematic reviews of interventions version 6.2 (updated February 2021). Cochrane., 2021. Available on: www.training.cochrane.org/handbook
  39. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med., 2009, 6(7), e1000097. doi: 10.1371/journal.pmed.1000097 PMID: 19621072
  40. Sterne, J.A.C.; Savović, J.; Page, M.J.; Elbers, R.G.; Blencowe, N.S.; Boutron, I.; Cates, C.J.; Cheng, H.Y.; Corbett, M.S.; Eldridge, S.M.; Emberson, J.R.; Hernán, M.A.; Hopewell, S.; Hróbjartsson, A.; Junqueira, D.R.; Jüni, P.; Kirkham, J.J.; Lasserson, T.; Li, T.; McAleenan, A.; Reeves, B.C.; Shepperd, S.; Shrier, I.; Stewart, L.A.; Tilling, K.; White, I.R.; Whiting, P.F.; Higgins, J.P.T. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ, 2019, 366, l4898. doi: 10.1136/bmj.l4898 PMID: 31462531
  41. Sterne, J.A.C.; Hernán, M.A.; Reeves, B.C.; Savović, J.; Berkman, N.D.; Viswanathan, M.; Henry, D.; Altman, D.G.; Ansari, M.T.; Boutron, I.; Carpenter, J.R.; Chan, A.W.; Churchill, R.; Deeks, J.J.; Hróbjartsson, A.; Kirkham, J.; Jüni, P.; Loke, Y.K.; Pigott, T.D.; Ramsay, C.R.; Regidor, D.; Rothstein, H.R.; Sandhu, L.; Santaguida, P.L.; Schünemann, H.J.; Shea, B.; Shrier, I.; Tugwell, P.; Turner, L.; Valentine, J.C.; Waddington, H.; Waters, E.; Wells, G.A.; Whiting, P.F.; Higgins, J.P.T. ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ, 2016, 355, i4919. doi: 10.1136/bmj.i4919 PMID: 27733354
  42. Petrakis, I.L.; Poling, J.; Levinson, C.; Nich, C.; Carroll, K.; Rounsaville, B. Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders. Biol. Psychiatry, 2005, 57(10), 1128-1137. doi: 10.1016/j.biopsych.2005.02.016 PMID: 15866552
  43. Vasile, D.; Vasiliu, O.; Mangalagiu, A.G.; Petrescu, B.M.; Sopterean, G.A.; Bratu, R.E.P. 3.b.001 Pharmacological management of alcohol dependence in chronic schizophrenia. Eur. Neuropsychopharmacol., 2013, 23, S429. doi: 10.1016/S0924-977X(13)70679-5
  44. Petrakis, I.L.; O’Malley, S.; Rounsaville, B.; Poling, J.; McHugh-Strong, C.; Krystal, J.H. Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology (Berl.), 2004, 172(3), 291-297. doi: 10.1007/s00213-003-1658-9 PMID: 14634716
  45. Batki, S.; Dimmock, J.; Ploutz-Snyder, R.; Meszaros, Z.; Canfield, K. Directly monitored naltrexone reduces heavy drinking in svhizophrenia: Preliminary analysis of a controlled trial: 411. Alcohol. Clin. Exp. Res., 2009, 33.
  46. Bratu, E.R.; Sopterean, G.A.P. 3.020 Comparison of the efficacies of naltrexone and acamprosate in the treatment of patients with chronic schizophrenia who are alcohol dependent. Eur. Neuropsychopharmacol., 2014, 24, S71-S72. doi: 10.1016/S0924-977X(14)70080-X
  47. Ralevski, E.; O’Brien, E.; Jane, J.S.; Dwan, R.; Dean, E.; Edens, E.; Arnaout, B.; Keegan, K.; Drew, S.; Petrakis, I. Treatment with acamprosate in patients with schizophrenia spectrum disorders and comorbid alcohol dependence. J. Dual Diagn., 2011, 7(1-2), 64-73. doi: 10.1080/15504263.2011.569440 PMID: 26954912
  48. Batki, S.; Dimmock, J.; Meszaros, Z. Extended-release naltrexone for alcohol dependence in patients with serious mental illness: 661. Alcohol. Clin. Exp. Res., 2010, 34(6)
  49. Batki, S.L.; Dimmock, J.A.; Wade, M.; Gately, P.W.; Cornell, M.; Maisto, S.A.; Carey, K.B.; Ploutz-Snyder, R. Monitored naltrexone without counseling for alcohol abuse/dependence in schizophrenia-spectrum disorders. Am. J. Addict., 2007, 16(4), 253-259. doi: 10.1080/10550490701389732 PMID: 17661192
  50. Vasile, D.; Vasiliu, O.; Sopterean, G.A.; Bratu, R.E.; Androne, F.; Vasile, F.P. 3.d.028 Effectiveness and tolerability of nalmefene in alcohol use dependence comorbid with schizophrenia. Eur. Neuropsychopharmacol., 2014, 24, S538. doi: 10.1016/S0924-977X(14)70861-2
  51. Maxwell, S.; Shinderman, M.S. Use of naltrexone in the treatment of alcohol use disorders in patients with concomitant major mental illness. J. Addict. Dis., 2000, 19(3), 61-69. doi: 10.1300/J069v19n03_05 PMID: 11076120
  52. Vasiliu, O.P. 796 Therapeutic management of young patients with schizoaffective disorder and alcohol use disorder dual diagnosis. Eur. Neuropsychopharmacol., 2020, 40, S450. doi: 10.1016/j.euroneuro.2020.09.585
  53. Petrakis, I.L.; Nich, C.; Ralevski, E. Psychotic spectrum disorders and alcohol abuse: A review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram. Schizophr. Bull., 2005, 32(4), 644-654. doi: 10.1093/schbul/sbl010 PMID: 16887890
  54. Grüner Nielsen, D.; Andersen, K.; Søgaard Nielsen, A.; Juhl, C.; Mellentin, A. Consistency between self-reported alcohol consumption and biological markers among patients with alcohol use disorder – A systematic review. Neurosci. Biobehav. Rev., 2021, 124, 370-385. doi: 10.1016/j.neubiorev.2021.02.006 PMID: 33581224
  55. Das, N.; Mahapatra, A.; Sarkar, S. Disulfiram induced psychosis: Revisiting an age-old entity. Asian J. Psychiatr., 2017, 30, 94-95. doi: 10.1016/j.ajp.2017.08.011 PMID: 28843144
  56. Fuller, R.; Roth, H.; Long, S. Compliance with disulfiram treatment of alcoholism. J. Chronic Dis., 1983, 36(2), 161-170. doi: 10.1016/0021-9681(83)90090-5 PMID: 6337171
  57. O’Farrell, T.J.; Bayog, R.D. Antabuse contracts for married alcoholics and their spouses: A method to maintain antabuse ingestion and decrease conflict about drinking. J. Subst. Abuse Treat., 1986, 3(1), 1-8. doi: 10.1016/0740-5472(86)90002-4 PMID: 3735473
  58. Krampe, H.; Ehrenreich, H. Supervised disulfiram as adjunct to psychotherapy in alcoholism treatment. Curr. Pharm. Des., 2010, 16(19), 2076-2090. doi: 10.2174/138161210791516431 PMID: 20482514
  59. Salles, J.; Ponté, C.; Schmitt, L. Psychotic decompensation during nalmefene treatment in a patient with schizoaffective disorder: A case report. J. Dual Diagn., 2019, 15(2), 118-121. doi: 10.1080/15504263.2019.1574367 PMID: 30829564
  60. Zhornitsky, S.; Rizkallah, É.; Pampoulova, T.; Chiasson, J.P.; Stip, E.; Rompré, P.P.; Potvin, S. Antipsychotic agents for the treatment of substance use disorders in patients with and without comorbid psychosis. J. Clin. Psychopharmacol., 2010, 30(4), 417-424. doi: 10.1097/JCP.0b013e3181e7810a PMID: 20631559
  61. Morris, P.L.P.; Hopwood, M.; Whelan, G.; Gardiner, J.; Drummond, E. Naltrexone for alcohol dependence: A randomized controlled trial. Addiction, 2001, 96(11), 1565-1573. doi: 10.1046/j.1360-0443.2001.961115654.x PMID: 11784454
  62. Volpicelli, J.R.; Rhines, K.C.; Rhines, J.S.; Volpicelli, L.A.; Alterman, A.I.; O’Brien, C.P. Naltrexone and alcohol dependence. Role of subject compliance. Arch. Gen. Psychiatry, 1997, 54(8), 737-742. doi: 10.1001/archpsyc.1997.01830200071010 PMID: 9283509
  63. Mason, B.J.; Lehert, P. Acamprosate for alcohol dependence: A sex-specific meta-analysis based on individual patient data. Alcohol. Clin. Exp. Res., 2012, 36(3), 497-508. doi: 10.1111/j.1530-0277.2011.01616.x PMID: 21895717
  64. Greenfield, S.F.; Pettinati, H.M.; O’Malley, S.; Randall, P.K.; Randall, C.L. Gender differences in alcohol treatment: An analysis of outcome from the COMBINE study. Alcohol. Clin. Exp. Res., 2010, 34(10), 1803-1812. doi: 10.1111/j.1530-0277.2010.01267.x PMID: 20645934
  65. Jackson, J.J.; Thoemmes, F.; Jonkmann, K.; Lüdtke, O.; Trautwein, U. Military training and personality trait development: Does the military make the man, or does the man make the military? Psychol. Sci., 2012, 23(3), 270-277. doi: 10.1177/0956797611423545 PMID: 22275337
  66. Spence, N.J.; Henderson, K.A.; Elder, G.H., Jr Does adolescent family structure predict military enlistment? A comparison of post–high school activities. J. Fam. Issues, 2013, 34(9), 1194-1216. doi: 10.1177/0192513X12457347 PMID: 24000268
  67. Mankowski, M.; Tower, L.E.; Brandt, C.A.; Mattocks, K. Why women join the military: Enlistment decisions and postdeployment experiences of service members and veterans. Soc. Work, 2015, 60(4), 315-323. doi: 10.1093/sw/swv035 PMID: 26489352
  68. Xue, C.; Ge, Y.; Tang, B.; Liu, Y.; Kang, P.; Wang, M.; Zhang, L. A meta-analysis of risk factors for combat-related PTSD among military personnel and veterans. PLoS One, 2015, 10(3), e0120270. doi: 10.1371/journal.pone.0120270 PMID: 25793582
  69. Ray, L.A.; Oslin, D.W. Naltrexone for the treatment of alcohol dependence among African Americans: Results from the COMBINE Study. Drug Alcohol Depend., 2009, 105(3), 256-258. doi: 10.1016/j.drugalcdep.2009.07.006 PMID: 19717248
  70. Plebani, J.G.; Oslin, D.W.; Lynch, K.G. Examining naltrexone and alcohol effects in a minority population: Results from an initial human laboratory study. Am. J. Addict., 2011, 20(4), 330-336. doi: 10.1111/j.1521-0391.2011.00138.x PMID: 21679264
  71. Sanchez-Roige, S.; Palmer, A.A.; Clarke, T.K. Recent efforts to dissect the genetic basis of alcohol use and abuse. Biol. Psychiatry, 2020, 87(7), 609-618. doi: 10.1016/j.biopsych.2019.09.011 PMID: 31733789
  72. Castaldelli-Maia, J.M.; Malbergier, A.; de Oliveira, A.B.P.; Amaral, R.A.; Negrão, A.B.; Gonçalves, P.D.; Ventriglio, A.; de Berardis, D.; de Antonio, J.; Firigato, I.; Gattás, G.J.F.; de Toledo Gonçalves, F. Exploring the role of alcohol metabolizing genotypes in a 12-week clinical trial of naltrexone for alcohol use disorder. Biomolecules, 2021, 11(10), 1495. doi: 10.3390/biom11101495 PMID: 34680127
  73. Tek, C.; Srihari, V.; Tek, E. Successful acamprosate treatment of alcohol dependence in schizophrenia. Schizophr. Res., 2008, 106(2-3), 373. doi: 10.1016/j.schres.2008.08.010 PMID: 18804961
  74. Krystal, J.H.; Cramer, J.A.; Krol, W.F.; Kirk, G.F.; Rosenheck, R.A. Naltrexone in the treatment of alcohol dependence. N. Engl. J. Med., 2001, 345(24), 1734-1739. doi: 10.1056/NEJMoa011127 PMID: 11742047

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers